SynthesisFrontiers in pharmacology2026
Efficacy and safety of ropeginterferon in myeloproliferative neoplasms: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ropeginterferon alfa-2b (ropegIFN-α2b or ropeginterferon) has emerged as a therapeutic option for patients with myeloproliferative neoplasms, particularly polycythemia vera (PV), with potential disease-modifying effects. This systematic review aimed to evaluate the efficacy and safety of ropeginterferon across clinical and real-world studies. Methods: A systematic search of PubMed, Embase, and Web of Science was conducted to identify studies reporting clinical outcomes of ropeginterferon in patients with MPNs. An additional PubMed search was performed to capture recently published studies. Eligible studies were screened according to predefined inclusion criteria. Data on hematologic, molecular, clinical, and safety outcomes were extracted and narratively synthesized. A proportional meta-analysis was conducted for selected outcomes, including complete hematologic response (CHR), partial molecular response (PMR), and grade ≥3 cytopenias. Results: A total of 18 studies involving 1,836 patients were included. Pooled analysis demonstrated that CHR rates increased over time, from 26% at 3 months to 59% at 12 months, with an overall pooled estimate of 56% (95% CI: 46%-66%). PMR was achieved in 37% of patients (95% CI: 20%-59%), although with substantial heterogeneity. Molecular responses were supported by consistent reductions in Conclusion: RopegIFN-α2b demonstrates favorable efficacy and safety profiles in patients with MPNs, especially in PV, with evidence of progressive hematologic and molecular responses over time. These findings support its role as a potentially disease-modifying therapy, although further standardized and long-term studies, focusing on ET and MF, are needed. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261337306, identifier CRD420261337306.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.